CUE Cue Biopharma
Company Analysis
Latest News
🟢 Cue Biopharma is trading 5% up in pre-market on continued biotech-sector momentum
Cue Biopharma is trading 5.09% up now at $30.32, after extending gains from August 25 and August 26, with continued biotechnology-sector momentum cited as the...
🟢 Cue Biopharma is trading 5.9% up today on biotech-sector momentum
Cue Biopharma is trading 5.9% up now at $28.34, with continued biotechnology-sector momentum the strongest identified driver; XBI rose 2.06% during regular...
🟢 Cue Biopharma is trading 11.22% up today as XBI gains 2.06%
Cue Biopharma is trading 11.22% up at $25.78, with biotech-sector strength providing the primary support amid broader risk-on sentiment. - XBI is up 2.06%...
🟢 Cue Biopharma is trading 7.81% up today as biotech strength supports gains
Cue Biopharma is trading at $24.99, up 7.81%, supported primarily by biotech-sector strength. - Shares rebounded after falling from $34.20 on August 14 to...
🔴 Cue Biopharma is trading 5% down today after Purcell & Lefkowitz announced shareholder investigation
Cue Biopharma is trading at $22.77 (-5.05%) after Purcell & Lefkowitz announced a shareholder investigation into recent corporate actions. - Wall Street Zen...
Cue Biopharma Downgraded to Sell, Following Massive $24.14 Per Share Loss
Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from hold to sell on Sunday. This action contributes to a consensus sell rating for the company. The...
🔴 Cue Biopharma is trading 5.2% down today
Cue Biopharma is trading 5.2% down at $23.32 after reversing an early pre-market rebound. - No clear company-specific announcement was identified for August...
🟢 Cue Biopharma is trading 5.57% up in pre-market amid broader risk-on rebound
Cue Biopharma is trading 5.57% up in pre-market at $25.98, appearing to reflect broader pre-market risk appetite after the previous session’s selloff. -...
🔴 Cue Biopharma falls 5.0% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Cue Biopharma is trading 6.9% up today amid continued reaction to Q2 results
Cue Biopharma is trading 6.9% up at $28.08, continuing a volatile reaction to its August 14, 2026 second-quarter results and recent pipeline developments. -...
🟢 Cue Biopharma is trading 5% up in after-hours trading after earnings and a two-session slide
Cue Biopharma is trading 5.06% up in after-hours trading at $27.00, appearing to reflect continued post-earnings volatility and a rebound after two consecutive...
🔴 Cue Biopharma is trading 10% down today after senior executives sold substantial shareholdings
Cue Biopharma is trading 9.99% down at $24.88 after an August 18 disclosure that senior executives sold substantial shareholdings. - The legal chief sold...
Cue Biopharma's $153 Million Loss Dwarfs Revenue Gains — Can One-Time Charges Excuse the Sticker Shock?
Shares of Cue Biopharma plunged 13.7% to $29.53 as investors digested a second-quarter loss so large it made the company's genuine revenue progress almost...
🔴 Cue Biopharma is trading 13.65% down today after Q2 net loss rose to $153.1 million
Cue Biopharma is trading at $29.53, down -13.65% after August 14, 2026, Q2 earnings showed a $153.1 million net loss, versus $8.5 million a year earlier. -...
🔴 Cue Biopharma is trading 6.1% down today after second-quarter net loss widened to $153.1 million
Cue Biopharma is trading 6.1% down at $32.12 after investors reassessed its August 14 second-quarter results. - Revenue rose to $7.9 million from $3.0...
Cue Biopharma Q2 2026 Earnings Preview: What Analysts Expect on August 18, 2026
Analyst consensus points to Q2 revenue of $3.00 million and an EPS loss of -$1.69, while the stock currently trades at $34.20, significantly below the average...
Cue Biopharma Downgraded to Hold, Following $1.6 Million CEO Stock Sale
Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from buy to hold on Saturday. The action follows the company’s August 14 second-quarter earnings report....
Cue Biopharma second quarter 2026 revenue hits $7.9M as CUE-221 acquisition expenses drive losses
Cue Biopharma reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million year-over-year, driven by milestones from its Boehringer...
🔴 Cue Biopharma is trading 6.73% down in after-hours trading as immediate catalyst remains unclear
Cue Biopharma is trading 6.73% down at $31.90 after closing at $34.20 on August 14, 2026; the immediate catalyst remains unclear. - No confirmed...
🟢 Cue Biopharma is trading 11.33% up today with no confirmed catalyst
Cue Biopharma is trading 11.33% up at $34.60, with the cause unclear. - Gains extended from August 11 through August 13; no verified company-specific...